Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
Cardiol Therapeutics Inc Class A
CT9Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada. Address: 2265 Upper Middle Road East, Oakville, ON, Canada, L6H 0G5
Analytics
Zielpreis von Wall Street
15.83 CADKGV
–Dividendenrendite
–Schlüsselzahlen CT9
- Gewinnspanne
- Gesamtumsatz
- Bruttogewinn
Dividenden-Analyse CT9
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y>5 - expected 5-9 dividend yield on cost over 10Y<5 - expected <5 dividend yield on cost over 10YMaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–Dividendenwachstum über 5 Jahre
–Kontinuierliches Wachstum
–Ausschüttungsquote 5-Jahres-Durchschnitt
–Verlauf der Dividende CT9
- Auszahlungsquote
- Dividends
- Dividendenrendite
Bewertung der Aktie CT9
- KUV
- KGV
- Kurs-Buchwert-Verhältnis
Finanzen CT9
Verfolgen Sie wichtige Kennzahlen für jede Aktie problemlos an einem Ort
Premium bekommenErgebnisse | 2019 | Dynamik |